Collaboration and License Agreements (Tables)

3 Months Ended

Jun. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Collaboration and License Agreements

The following table presents changes in the Company’s contract liabilities during the three months ended June 30, 2022 (in thousands):

	Balance at March 31, 2022		Additions		Imputed Interest		Deductions		Balance at June 30, 2022
Contract liabilities:
Deferred revenue (1)	$	476,270	$	—	$	—	$	(25,141)	$	451,129
Cost share advance from Pfizer (2)	$	33,818	$	—	$	568	$	(25,831)	$	8,555

(1) Includes $100.6 million and $350.6 million presented as current and non-current, respectively, on the unaudited condensed consolidated balance sheet as of June 30, 2022. Includes $100.6 million and $375.7 million presented as current and non-current, respectively, on the unaudited condensed consolidated balance sheet as of March 31, 2022.

(2) Includes $8.6 million presented as current on the unaudited condensed consolidated balance sheet as of June 30, 2022. Includes $33.8 million presented as current on the unaudited condensed consolidated balance sheet as of March 31, 2022.